By Fineline Cube 
Ocumension Therapeutics (HKG: 1477), a Chinese ophthalmology specialist, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved its Phase III clinical study for OT-802 (pilocarpine eye drops) for presbyopia. This marks a significant step in the development of a novel treatment option for age-related vision challenges.
OT-802 Mechanism and Advantages
OT-802, independently developed by Ocumension, leverages the well-established ophthalmic treatment mechanism of pilocarpine. By inducing pupil constriction, it enhances depth of field and improves near-to-intermediate vision. Ocumension’s proprietary liquid-liquid dual-chamber technology ensures the stability of pilocarpine eye drops at a neutral pH, optimizing therapeutic efficacy and minimizing side effects.
Clinical Potential
Preclinical data demonstrate that OT-802 offers rapid onset, low adverse reactions, and favorable comfort and safety profiles. This innovation underscores Ocumension’s commitment to advancing ophthalmic treatments and addressing the growing need for effective presbyopia solutions.-Fineline Info & Tech